Stock listing
Stuttgart:6K9 Context Therapeutics Inc. Aktie
German listing (Stuttgart) of Context Therapeutics Inc. · home listing NASDAQ:CNTX
Follow Context Therapeutics Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CNTX
$0.244 USD +0.004 (+1.5%)
Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CNTX
- Day range
- $0.222 – $0.270 USDOct 16, 2026
- Volume
- 2.24M sharesOct 16, 2026
- Market value
- $22.42M USDAt the close on Oct 16, 2026 · price × 91.88M shares outstanding
- Ticker
- Stuttgart:6K9
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Sep 9, 2026
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 37 slides
Latest news
Decks
Investor Presentation (August 2026)
Investor deck · 37 slides · August 2026
Technical Presentation (June 2026)
Technical · 31 slides · Jun 15, 2026
Investor Presentation (June 2026)
Investor deck · 44 slides · Jun 15, 2026
Investor Presentation (March 2026)
Investor deck · 35 slides · Mar 23, 2026
Context Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 72 in all · newest Sep 9, 2026 · oldest 2021
- Decks
- 25 decks · latest August 2026
Where Context Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CNTX · Home listing | NASDAQ | United States | USD |
| gettex:6K9 | gettex | Germany | EUR |
| LS Exchange:A3CWBU | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3CWBU | Lang & Schwarz | Germany | EUR |
| BOATS:CNTX | BOATS | United States | USD |
| Frankfurt:6K9 | Frankfurt | Germany | EUR |
| Munich:6K9 | Munich | Germany | EUR |
| Stuttgart:6K9 · This page | Stuttgart | Germany | EUR |
| Tradegate:6K9 | Tradegate | Germany | EUR |
Log in to ask 6ix AI your own questions about Context Therapeutics Inc.